Associate Electrophysiology Mapping Specialist

Medtronic reported its highest annual revenue growth in a decade in fiscal 2026, with first-quarter fiscal 2027 revenues jumping 13.7%. The medical device maker has undertaken strategic changes, including exiting less profitable businesses and investing in new technology such as its Hugo surgical robot, recently launched in the US market. Management increased full-year guidance for fiscal 2027 after just one quarter, signalling confidence in the company's direction. The stock has risen 15% over the past three months but remains 30% below its 2021 high. Medtronic boasts a 48-year dividend increase streak and currently offers an above-market dividend yield. After years of being weighed down by bureaucracy and too many business lines, the company appears to have passed an important inflection point in its turnaround efforts.

Inside Hadassah hospitals: insights from Prof. Yoram Weiss. From artificial intelligence and personalized cancer treatments to organoids, robotics and advanced rehabilitation, Hadassah Medical Organization (HMO) Director General Prof. Yoram Weiss, MD, offered an inside look at the innovative work happening today at Hadassah hospitals in Israel during a recent visit to the New York City headquarters of Hadassah: The Women's Zionist Organization of America. Speaking to Hadassah staff, Prof. Weiss shared some of the latest advances underway at Hadassah hospitals in Jerusalem and offered a glimpse of what comes next as HMO continues to expand its medical, research and technological capabilities. He spoke of HMO's mission, stressing its commitment to training and teaching and to serving as a bridge to peace. "We're doing that every day, every moment," he said. Among the advances Prof. Weiss highlighted was HMO's growing leadership in robotic surgery. Hadassah hospitals played an early role in the development of the Mazor Robotics Renaissance(R) Guidance System for spine surgery and today is working closely with Medtronic on the development of its Hugo robotic-assisted surgery (RAS) system. HMO's expertise has also made it a sought-after partner for some of the world's leading healthcare and technology companies. HMO works with GE HealthCare on advanced imaging and theranostics and with Roche Pharmaceuticals on personalized cancer medicine, drawing on the hospitals' extensive clinical data and artificial intelligence capabilities. Prof. Weiss also pointed to HMO's work with organoids, tiny three-dimensional models grown from patients' cells. Hadassah hospitals are already using organoids to help determine which treatments are most likely to work for patients with cystic fibrosis, helping to identify the right medication for each individual. "We're giving better medicine to the patient much faster," Prof. Weiss said. "No more trial and error." As part of its commitment to global cooperation and teaching, Prof. Weiss noted that HMO researchers are leading a monthlong hands-on training course in Massachusetts this summer to share expertise with medical researchers and students from around the world. He also highlighted HMO's expanding work using artificial intelligence. "We are in the middle of a revolution when it comes to medical management," Prof. Weiss said. Already, physicians are working with an AI system in their routine work. Drawing on computerized medical data - HMO started early, in the 1980s - Hadassah has brought together genomic, laboratory, clinical and imaging information to create a "data lake," giving physicians a tool to better understand individual patients and how to tailor their care. That's one reason the pharmaceutical company Roche chose Hadassah as one of a handful of hospitals worldwide collaborating on an initiative related to the genetic identification of cancer, Prof. Weiss said. Other advances include HMO's work in CAR-T cell therapy, theranostics, 3D printing and robotic surgery. HMO is developing what Prof. Weiss said will be Israel's largest robotic surgery center and is the first hospital outside the United States set to implement the Ion robotic bronchoscopy system, which can reach deep into the lungs to obtain biopsies. But amid a presentation filled with medical breakthroughs and technology, Prof. Weiss repeatedly returned to what he considers Hadassah's greatest strengths: its people and its mission. Hadassah hospitals treat about 1 million patients each year, serving Jerusalem's extraordinarily diverse population. "When they come to Hadassah, they feel that Hadassah is a place for healing, and that they can come to Hadassah and feel safe," Prof. Weiss said. The hospitals are also a place where staff model coexistence. Hadassah trains and employs physicians and nurses from around the world, including approximately 70 residents and fellows from the Palestinian Authority. HMO medical teams provide humanitarian care internationally, including at a clinic on the Ukraine-Poland border that treated some 35,000 people following Russia's invasion of Ukraine. "Hadassah, in a way, is a bubble of peace within the havoc of the Middle East," Prof. Weiss said. Looking ahead, HMO is developing a 10-year plan for its Jerusalem campuses as it continues investing in new facilities, technology and the next generation of medical professionals. Prof. Weiss emphasized that all of those advances depend on the people behind them, the physicians, researchers, nurses and staff who bring Hadassah's mission to life every day. And as HMO plans for what comes next, he said the goal is clear: "We need to have a dream. We need to look to the future."

Boston Scientific's SCS leads linked to 1,081 serious injuries in FDA alert. Boston's recall comes at a time where several players in the medtech industry are facing personal injury lawsuits over SCS system malfunctions. The US Food and Drug Administration (FDA) has issued an alert over Boston Scientific's recall of a lead kit used with its spinal cord stimulator (SCS) system at a time when the company and other medtech industry players are facing lawsuits over SCS systems malfunctioning. In a letter sent to customers on 17 June, Boston said the body of its Infinion CX leads, which are compatible with its SCS systems for relieving chronic pain in the back and limbs, including Spectra WaveWriter and WaveWriter Alpha, may experience "mechanical stress at the anchor site", an issue that may result in high impedance measurements or lead fractures. These abnormal impedance measurements may lead to inadequate stimulation and/or additional intervention, including lead explant and replacement, the company stated as per the FDA alert. SCS is a form of neuromodulation used for treating chronic, severe nerve pain in the trunk, arms, or legs when conservative treatments have failed. As of 27 May, Boston Scientific has reported 1,081 serious injuries and no deaths associated with this issue. While the action does not affect SCS devices that have already been implanted, Boston now recommends that all unused Infinion CX leads be removed from where they are used or sold. Boston's recall comes at a time in which the company, alongside other players in the medtech industry with SCS systems, including Medtronic and Abbott, are facing lawsuits regarding device failure, shocks, and lack of pain relief. A series of lawsuits pertaining to Boston's SCS systems were formally centralised into a single federal multidistrict litigation (MDL) on 5 June 2026 for coordinated proceedings. Meanwhile, in August 2026, Abbott opposed the creation of a proposed MDL seeking to consolidate 23 personal injury lawsuits involving its SCS systems into a single proceeding in the Central District of California. According to GlobalData analysis, the global neurology devices market, of which SCS systems are a part, is projected to reach a valuation above $25bn in 2034. Meanwhile, a recent report from GlobalData forecasts that the SCS market will be worth $3.5bn in North America in 2033. Give your business an edge with its leading industry insights.